NetworkNewsBreaks – Coherus BioSciences Inc. (NASDAQ: CHRS) Featured in Mizuho Securities Research Report
Coherus BioSciences (NASDAQ: CHRS) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Udenyca's alternative dosing formulations and tori clinical programs, among other topics, were discussed. Key tidbits below: Udenyca. Net Udenyca sales were $83MM in 1Q21 compared to $110MM in 4Q20, a ~25% qoq decrease that according to management was a result of: 1) Inventory changes (inventory business days are as follows: end of 3Q20 11 business days, end of 4Q20 21 business days, end of 1Q21 12 business days), and by our math, each business day is worth $1.5MM; and…







